KLAQ

Unit Split

KL Acquisition Corp

Sponsors: KL Sponsor
Underwriter: Goldman Sachs & Co
Raised
$287M
CIK
1823323
Focus
Healthcare, Life Sciences
External link: SEC Filings

SPAC Team

Leadership

Doug Logigian, our Chief Executive Officer and Chairman of our board of directors , has been a Partner and the President of Kennedy Lewis Investment Management LLC, an opportunistic credit manager (which we refer to as KLIM), since April 2020. Prior to that, he was at Blackstone, a private equity alternative investment management firm, from July 2006 to December 2019, where he most recently served as a Senior Managing Director and sat on the investment committee for distressed funds and special situations funds of GSO Capital Partners, a division of Blackstone. Mr. Logigian also served on Blackstone’s Capital Markets Committee and oversaw the operations of the trading desk and transacted in all of the asset classes in which GSO Capital Partners trafficked. Prior to that, Mr. Logigian worked as an Associate at Citibank where he was responsible for managing a book of high yield cash bonds and credit default swaps on the credit trading desk from September 2003 to July 2006. Mr. Logigian served on the Board of Directors for Seneca Mortgage Management, a real estate investment company that invests in mortgage servicing rights, from September 2013 to February 2019. Mr. Logigian received a B.A. degree in History with honors from Harvard University. Mr. Logigian is well qualified to serve on our board of directors due to his significant experience in capital markets and investment.

Richard Gumer, our Chief Financial Officer, Secretary and director , has been the Managing Director, Head of Life Sciences of KLIM since October 2018, where he is responsible for providing non-dilutive, growth capital to commercial-stage life sciences companies. From February 2013 to October 2018, he was the Chief Executive Officer and Co-Founder of Life Sciences Alternative Funding LLC, a company providing capital to commercial-stage life sciences companies (or LSAF). Prior to that, he was a Senior Advisor at Cowen Healthcare Royalty Partners, a healthcare investment firm, and responsible for medical device and diagnostics investments from December 2010 to May 2012. Mr. Gumer served on several board of directors, including as the director and member of the executive committee and audit committee of Stimwave Technologies, Inc., a medical device company, from December 2019 to October 2020, as the director and member of the compensation committee of VisionCare Inc., a medical device company, from April 2016 to September 2019, as a director of Integrated Diagnostics Inc., a company conducting medical research and providing development services, from August 2017 to December 2018. He has an A.B. degree in Biochemistry from Brown University and an MBA degree in Finance from University of California, Berkeley. Mr. Gumer is well qualified to serve on our board of directors due to his significant experience in investment in life science and healthcare companies, as well as his service on the boards of directors of several private companies.

David Kho, our Chief Operating Officer and director , is currently a Managing Director of KLIM and previously served as its Director from December 2019 to December 2020 and Vice President from April 2019 to December 2019. He was a Vice President at Bridge Bank, a full-service commercial bank, responsible for originating and managing credits in the life sciences industry, from August 2018 to April 2019. Before joining Bridge Bank, he was a Director of Mergers and Acquisitions at Yaras Group, an investment company, where he oversaw mergers and acquisitions from January 2018 to July 2018. Prior to that, he was a Vice President with LSAF, where he reviewed all new business opportunities and built all internal models from December 2014 to January 2018. From April 2016 to March 2018, he was a director of the board of VisionCare, Inc., a medical device company with an FDA-approved implant for the treatment of age-related macular degeneration. He worked as a Vice President at Square 1 Bank, a full-service commercial bank, where he managed a loan portfolio of venture-backed medical device, diagnostics, biotechnology and healthcare IT/services companies, from September 2008 to December 2014. Mr. Kho received a B.S. degree in Business Administration from the University of North Carolina at Chapel Hill. Mr. Kho is well qualified to serve on our board of directors due to his experience in financing and mergers and acquisitions for healthcare companies.

James L. Bierman will serve as one of our directors as of the effective date of the registration statement. Mr. Bierman served as President and Chief Executive Officer of Owens & Minor, Inc., a Fortune 500 company and a distributor of medical and surgical supplies, from September 2014 to June 2015. Previously, he served in various other senior roles at Owens & Minor, including President and Chief Operating Officer from August 2013 to September 2014, Executive Vice President and Chief Operating Officer from March 2012 to August 2013, Executive Vice President and Chief Financial Officer from April 2011 to March 2012, and Senior Vice President and Chief Financial Officer from June 2007 to April 2011. From 2001 to 2004, Mr. Bierman served as Executive Vice President and Chief Financial Officer at Quintiles Transnational Corp., a provider of pharmaceutical outsourcing services. Prior to joining Quintiles Transnational, Mr. Bierman was a partner at Arthur Andersen LLP. Mr. Bierman currently serves on the board of directors of Tenet Healthcare Corporation (NYSE: THC), MiMedx Group, Inc. (Nasdaq: MDXG), Novan, Inc. (Nasdaq: NOVN) and previously served on the boards of directors of Owens & Minor, Inc. (NYSE: OMI) and Team Health Holdings, Inc. (formerly TMH). Mr. Bierman earned his B.A. in History and Economics from Dickinson College and his M.B.A. at Cornell University’s Johnson Graduate School of Management. Mr. Bierman is well qualified to serve on our board of directors due to his extensive experience in finance, healthcare industry and his board experience with public companies.

Gregory D. Casciaro will serve as one of our directors as of the effective date of the registration statement. Mr. Casciaro has 39 years of medical device experience and has held leadership roles in both public and private companies. Mr. Casciaro has been a special advisor to the board of directors of Cardiac Dimensions, Inc., a medical device company developing products to treat heart failure, since March 2020. Previously, he was the Chief Executive Officer, President and a director of Cardiac Dimensions, Inc. from December 2015 to February 2020. From June 2010 to August 2014, Mr. Casciaro served as the President, Chief Executive Officer and a director of AccessClosure, Inc., a medical device company that was acquired by Cardinal Health, Inc. (NYSE: CAH). From September 2004 to December 2009, Mr. Casciaro was the Chief Executive Officer, President and a member of the board of directors of XTENT, Inc., a medical device company that was acquired by Biosensors International Group, Ltd. (SGX: BIG). From February 2000 to August 2003, Mr. Casciaro served as the President, Chief Executive Officer and a director of Orquest Inc., a private company manufacturing and selling bio-therapeutic products to the orthopedic market which was acquired by DePuy Acromed, a division of Johnson and Johnson (NYSE: JNJ). From January 1995 to December 1999, he was President, Chief Executive Officer and a director at General Surgical Innovations, Inc. (Nasdaq: GSII), a laparoscopic surgical equipment manufacturer that was acquired by United States Surgical, a division of Tyco Healthcare Group (NYSE: TYC). Prior to General Surgical Innovations, Mr. Casciaro held executive and management positions at Devices for Vascular Intervention, a division of Guidant Corporation (NYSE: GDT), from June 1991 to December 1994, and at North American Instrument Corporation from June 1982 to January 1991. Mr. Casciaro has been a member of the board of directors of QT Vascular Ltd. (SGX: QTV), a Singaporean-listed company engaged in the design, assembly and distribution of therapeutic solutions for the minimally invasive treatment of complex vascular diseases, since 2001. From September 2014 to October 2017, he was a member of the board of directors of Apama Medical Inc., a medical device company focused on atrial fibrillation technologies which was acquired by Boston Scientific Corporation (NYSE: BSX) in October 2017. Mr. Casciaro previously served as a director for AngioDynamics, Inc. (Nasdaq: ANGO) from March 2004 to November 2008, Dextera Surgical from December 2014 to February 2018 and Kerberos Proximal Solutions from April 2005 to September 2006 when the company was acquired by Fox Hollow Technologies. Mr. Casciaro graduated from Marquette University with a B.S. in Business Administration. Mr. Casciaro is well qualified to serve on our board of directors due to his extensive management experience with growth companies and in mergers and acquisitions in the medical device industry.

Andrew A. Krakauer will serve as one of our directors as of the effective date of the registration statement. Prior to his retirement in October 2016, Mr. Krakauer was Chief Executive Officer of Cantel Medical Corp. (NYSE: CMD), a provider of infection control products and services (“Cantel”). During his 12 years at Cantel, Mr. Krakauer served in various executive and senior level positions, including Chief Executive Officer from November 2014 to July 2016, President and Chief Executive Officer from March 2009 to November 2014, President from April 2008 to March 2009, and Executive Vice President and Chief Operating Officer from August 2004 through April 2008. Mr. Krakauer also served as a member of Cantel’s board of directors from 2009 to 2016. Prior to joining Cantel, Mr. Krakauer was President of the Ohmeda Medical Division of Instrumentarium Corp. (which was acquired by General Electric Company in 2003), a provider of medical devices, from 1998 to 2004. Mr. Krakauer has been a director of Teleflex Incorporated (NYSE: TFX), a provider of specialty medical devices and technologies, since January 2018, and currently serves as a member of its Compensation Committee. Mr. Krakauer received his B.A. in Economics from State University of New York at Binghamton and his M.B.A. in Finance and Marketing from The University of Chicago. Mr. Krakauer is well qualified to serve on our board of directors due to his extensive senior executive management experience in the medical device industry.

Rafael Torres will serve as one of our directors as of the effective date of the registration statement. Mr. Torres has been senior vice president for strategy & corporate development at Varian Medical Systems, Inc. (NYSE: VAR), a cancer treatment and solutions company, since May 2015. He has been a member of the executive leadership team and of the strategy and investment management committees. Prior to joining Varian Medical Systems, Mr. Torres served as senior managing director, global head of healthcare for GE Ventures from July 2011 to April 2015, where he was a member of its senior leadership committee. He was the managing director and head of healthcare at GE Equity from January 2006 to July 2011, where he led healthcare investing. Between November 2001 and December 2004, he worked at GE Healthcare in corporate development and acquisition integrations in Milwaukee, London and Princeton. Prior to GE Healthcare, he worked as a financial institutions analyst at Citibank N.A. from August 1995 and August 1998. Mr. Torres holds a B.A. in economics from the Universidad del Pacifico in Lima, Peru and an MBA degree from Harvard Business School. Mr. Torres is well qualified to serve on our board of directors due to his experience in healthcare industry and capital investment.